Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols

Online veröffentlicht: 07. Dez. 2018

Seitenbereich: 87 - 97

Akzeptiert: 16. Juli 2018

DOI: https://doi.org/10.2478/acph-2019-0002

Schlüsselwörter

ovarian cancer, carboplatin plus paclitaxel, topotecan, bevacizumab, docetaxel

© 2019 Saima Sattar et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.